Addex Raises $5.0M Via Secondary Equity Offering Of 1.3M ADSs At $0.95
Addex Therapeutics Ltd (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with a